IMMUNOVIA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.055 SEK | +2.75% |
|
+17.16% | +15.97% |
| Sales 2021 | 844K 77.15K 6.17M | Sales 2022 | 1.14M 105K 8.38M | Capitalization | 595M 54.41M 4.35B |
|---|---|---|---|---|---|
| Net income 2021 | -156M -14.26M -1.14B | Net income 2022 | -168M -15.36M -1.23B | EV / Sales 2021 | 1,710 x |
| Net cash position 2021 | 254M 23.23M 1.86B | Net cash position 2022 | 68.47M 6.26M 501M | EV / Sales 2022 | 460 x |
| P/E ratio 2021 |
-10.9
x | P/E ratio 2022 |
-3.54
x | Employees | 11 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 75.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Immunovia AB
More press releases
| 1 day | +2.75% | ||
| 1 week | +17.16% | ||
| Current month | +50.22% | ||
| 1 month | +50.00% | ||
| 3 months | +12.66% | ||
| 6 months | +282.68% | ||
| Current year | +15.97% |
1 week
1.87
2.60
1 month
1.312.85
Current year
1.153.00
1 year
0.514.90
3 years
0.51141.50
5 years
0.51298.50
10 years
0.51298.50
| Managers | Title | Age | Since |
|---|---|---|---|
Jeff Borcherding
CEO | Chief Executive Officer | - | - |
| Director of Finance/CFO | 62 | 31/03/22 | |
Karl Stone
COO | Chief Operating Officer | 61 | 28/02/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 08/12/16 | |
Peter Andersen
CHM | Chairman | 67 | 31/12/19 |
Michael Löfman
BRD | Director/Board Member | - | 21/05/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2.055 | +2.75% | 1,008,622 |
| 25/04/24 | 2 | -4.76% | 689,247 |
| 24/04/24 | 2.1 | +9.72% | 1,041,782 |
| 23/04/24 | 1.914 | -7.31% | 1,067,817 |
| 22/04/24 | 2.065 | +17.73% | 3,201,853 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm
More quotes
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunoviaâs test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Calendar
29/04/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +15.97% | 8.49M | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -7.14% | 716M | |
| -18.10% | 682M |
- Stock Market
- Equities
- IMMNOV Stock
